Intellia Therapeutics to Present at October Healthcare Investor Conferences
30 Septembre 2019 - 2:00PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, will present at
the following upcoming healthcare conferences in October:
Monday, October 7, 2019Chardan 3rd
Annual Genetic Medicines ConferenceLocation: New York,
NYTime: 9:00 am ET
Tuesday, October 8, 2019Jefferies Gene
Therapy/Editing SummitLocation: New York, NYTime: 8:35 am
ET
A live webcast of Intellia’s presentations at the Chardan and
Jefferies conferences will be accessible through the Events and
Presentations page of the Investor Relations section of the
company’s website at www.intelliatx.com. To access the webcasts,
please log on to the Intellia website approximately 15 minutes
prior to the start time to ensure adequate time for any software
downloads that may be required. A replay of the webcasts will be
available on Intellia’s website for approximately 14 days following
each conference. About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Intellia Contacts:
Investors:Lina LiAssociate DirectorInvestor
Relations+1 857-706-1612lina.li@intelliatx.com
Media:Jennifer Mound SmoterSenior Vice
PresidentExternal Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024